Labcorp declares $0.72 quarterly dividend
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Labcorp Holdings Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.72 per share of common stock. The dividend will be paid on June 11, 2026 to stockholders who are on record at the close of business on May 29, 2026.
The company highlights its global scale, noting nearly 71,000 employees serving clients in about 100 countries and performing more than 750 million tests annually, as well as providing support for 85% of new drugs and therapeutic products approved by the FDA in 2025.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Quarterly dividend: $0.72 per share
Dividend record date: May 29, 2026
Dividend payment date: June 11, 2026
+4 more
7 metrics
Quarterly dividend
$0.72 per share
Cash dividend on common stock declared by Board
Dividend record date
May 29, 2026
Stockholders of record eligible for $0.72 dividend
Dividend payment date
June 11, 2026
Scheduled date to pay $0.72 per-share dividend
Employees
Nearly 71,000
Global workforce supporting Labcorp operations
Countries served
Approximately 100
Geographic reach of Labcorp’s clients
Annual tests performed
More than 750 million
Diagnostics volume for patients worldwide
FDA approvals supported
85% of new drugs and therapeutic products in 2025
Share of 2025 FDA approvals Labcorp supported
Key Terms
cash dividend, stockholders of record, quarterly dividend, Inline XBRL, +1 more
5 terms
cash dividend financial
"declared a cash dividend of $0.72 per share of common stock"
A cash dividend is a payment made by a company to its shareholders directly in money, usually on a regular schedule. It is a way for investors to receive a portion of the company's profits, similar to earning interest or a bonus for holding the company's stock. Cash dividends provide income to shareholders and can indicate the company's financial health and stability.
stockholders of record financial
"to stockholders of record as of the close of business on May 29, 2026"
Stockholders of record are the people or entities whose names appear on a company's official shareholder list on a specific cutoff date set by the company or its transfer agent; only those listed are entitled to receive dividends, vote at shareholder meetings, or participate in other corporate actions. Think of it like a guest list for an event: being on the list on the set day determines who gets the benefits and rights, so investors must own shares before the cutoff to qualify.
quarterly dividend financial
"Labcorp Declares Quarterly Dividend"
A quarterly dividend is a payment a company gives to its shareholders four times a year, usually as a share of its profits. It's like getting a small bonus every few months for owning the company's stock, which can provide a steady income. Investors watch these payments to see how well a company is doing and whether it’s a good investment.
Inline XBRL regulatory
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
laboratory services financial
"a global leader of innovative and comprehensive laboratory services"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What dividend did Labcorp (LH) declare in this 8-K filing?
Labcorp declared a quarterly cash dividend of $0.72 per share of common stock. This payment rewards current shareholders with direct cash returns, reflecting the company’s decision to distribute part of its capital to stockholders rather than retaining all earnings.
When is the record date for Labcorp’s $0.72 dividend?
The record date for Labcorp’s $0.72 per share dividend is May 29, 2026. Investors must be stockholders of record at the close of business that day to be eligible to receive the dividend payment declared by the company’s Board of Directors.
When will Labcorp (LH) pay its declared quarterly dividend?
Labcorp will pay the declared $0.72 per share quarterly dividend on June 11, 2026. Eligible stockholders are those recorded on the company’s books as of May 29, 2026, aligning with the standard record-date and pay-date structure for cash dividends.
How large is Labcorp’s global operations footprint mentioned in the filing?
Labcorp reports nearly 71,000 employees serving clients in approximately 100 countries. The company also notes performing more than 750 million tests annually, underscoring the scale of its diagnostics and drug development laboratory services worldwide.
What role did Labcorp play in FDA drug approvals in 2025?
Labcorp states it provided support for 85% of new drugs and therapeutic products approved by the FDA in 2025. This indicates deep involvement in clinical development and testing, emphasizing the company’s importance across pharmaceutical and biotechnology research pipelines.
What is the key purpose of this Labcorp 8-K filing?
The 8-K primarily discloses the Board’s decision to declare a $0.72 per share quarterly cash dividend. It also furnishes a press release as an exhibit, formally communicating the dividend terms, record date, and payment date to the market and shareholders.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
(Date of earliest event reported)
(Exact Name of Registrant as Specified in its Charter)
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| , | ||||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(Registrant’s telephone number including area code) 336 -229-1127
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure | ||||
Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced on April 9, 2026, that its Board of Directors has declared a cash dividend in the amount of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. | |||||||
| Exhibit | Exhibit Name | |||||||
| Exhibit 99.1 | Press release dated April 9, 2026 issued by Labcorp Holdings Inc. | |||||||
| Exhibit 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LABCORP HOLDINGS INC.
Registrant
| Date: April 9, 2026 | By: | /s/ KATHRYN W. KYLE | ||||||
| Kathryn W. Kyle | ||||||||
| Executive Vice President, Chief Legal Officer and Corporate Secretary | ||||||||
FOR IMMEDIATE RELEASE
| Media | Investors | |||||||
| Racquel White | Dewey Steadman | |||||||
| Media@Labcorp.com | Investor@Labcorp.com | |||||||
Labcorp Declares Quarterly Dividend
BURLINGTON, N.C., April 9, 2026 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11, 2026, to stockholders of record as of the close of business on May 29, 2026.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science and accelerates innovations to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for 85% of the new drugs and therapeutic products approved in 2025 by the FDA, and performed more than 750 million tests annually for patients around the world. Learn more about us at www.labcorp.com.